NCT06264986

Brief Summary

The goal of this clinical trial is to evaluate the effects of short-term root extract ashwagandha supplementation on exercise performance in female footballers. The main question it aims to answer are: Will short-term supplementation of root extract ashwagandha improve muscle strength markers in female footballers? Will short-term supplementation of root extract ashwagandha improve perception of recovery following high-intensity exercise in female footballers? Participants will either supplement 600mg (5% withanolides) root extract ashwagandha or placebo once a day for 28 days. There will be three data points: baseline, 14 days and 28 days. Researchers will compare values of intervention against placebo to see if there is an effect on muscle strength or perception of recovery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 13, 2024

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

January 31, 2024

Completed
20 days until next milestone

First Posted

Study publicly available on registry

February 20, 2024

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 21, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 27, 2024

Completed
9 months until next milestone

Results Posted

Study results publicly available

January 9, 2025

Completed
Last Updated

January 9, 2025

Status Verified

January 1, 2025

Enrollment Period

1 month

First QC Date

January 31, 2024

Results QC Date

June 27, 2024

Last Update Submit

January 3, 2025

Conditions

Outcome Measures

Primary Outcomes (5)

  • Increased Lower Body Muscle Strength 1/2

    Jump strength, assessed by Peak Power, is calculated based on jump height (in centimetres) and body mass (in kilograms) using this formula Peak power (W) = (60.7) × (jump height \[cm\]) + 45.3 × (body mass \[kg\]) - 2055 \[1\]. Jumps are measured using a clinically validated open-source jump mat (Chronojump Bocosystems) to ensure accuracy. The highest recorded value is used for analysis. 1\. Sayers, S. P.; Harackiewicz, D. V.; Harman, E. A.; Frykman, P. N.; Rosenstein, M. T. Cross-Validation of Three Jump Power Equations. Medicine and science in sports and exercise 1999, 31 (4), 572-577. https://doi.org/10.1097/00005768-199904000-00013.

    28 days

  • Increased Maximum Voluntary Muscle Strength

    Hand grip strength. This will be measured with a CAMRY digital hand dynamometer and the unit of measurement will be kilograms.

    28 days

  • Increased Upper Body Muscle Strength and Explosiveness

    Medicine ball throw using a 5 kilogram medicine ball. Participants will throw a medicine ball while standing. The distance of the throw will be measured in centimetres.

    28 days

  • Improved Overall Muscle Strength

    Rate of perceived exertion (RPE) using the Borg Scale measuring the difficulty of high-intensity exercise. 1 represents a score of very light activity, and 10 represents a score of maximum effort activity.

    28 days

  • Increased Lower Body Muscle Strength in 2/2

    Lower body muscle strength is assessed using the countermovement jump (CMJ) and squat jump (SJ) tests, two validated measures of lower body explosive power. Each participant performs a single jump for each test on a clinically validated open-source jump mat (Chronojump Bocosystems), which records jump height in centimetres. The jump mat uses precise force and time measurements to calculate height, ensuring reliable data output. Participants receive standardised instructions and a demonstration before testing to ensure consistency and accuracy.The highest recorded value is used for analysis.

    28 days

Secondary Outcomes (2)

  • Improved Perception of Wellbeing

    28 days

  • Improved Perception of Recovery

    28 days

Study Arms (2)

KSM-66

EXPERIMENTAL

600mg (5% withanolides) KSM-66 ashwagandha, hydroxypropyl methylcellulose capsule

Dietary Supplement: Ashwagandha

Placebo

PLACEBO COMPARATOR

600mg Gluten-free chickpea powder, hydroxypropyl methylcellulose capsule

Other: Placebo

Interventions

AshwagandhaDIETARY_SUPPLEMENT

The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.

Also known as: KSM-66, Root extract ashwagandha
KSM-66
PlaceboOTHER

600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days

Placebo

Eligibility Criteria

Age17 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsParticipants must be female or assigned female at birth
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Female
  • Playing football professionally
  • At a sub-elite to elite standard
  • Healthy and free of disease

You may not qualify if:

  • Active supplementation with other ergogenic aids
  • Medication or contraceptives (to not interfere with existing treatment)
  • Thyroid conditions (due to interaction with cortisol)
  • Diabetes or certain autoimmune conditions (to not interfere with existing treatment)
  • Active pregnancy (to not interfere with existing treatment)
  • Allergies to nightshades such as tomato, aubergine, potatoes and peppers
  • No signing of the consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Club Esportiu Seagull

Badalona, Barcelona, 08917, Spain

Location

Related Publications (2)

  • Bonilla DA, Moreno Y, Gho C, Petro JL, Odriozola-Martinez A, Kreider RB. Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis. J Funct Morphol Kinesiol. 2021 Feb 11;6(1):20. doi: 10.3390/jfmk6010020.

    PMID: 33670194BACKGROUND
  • Coope OC, Reales Salguero A, Spurr T, Paez Calvente A, Domenech Farre A, Jordan Fisas E, Lloyd B, Gooderick J, Abad Sangra M, Roman-Vinas B. Effects of Root Extract of Ashwagandha (Withania somnifera) on Perception of Recovery and Muscle Strength in Female Athletes. Eur J Sport Sci. 2025 Mar;25(3):e12265. doi: 10.1002/ejsc.12265.

MeSH Terms

Interventions

Ashwagandha

Limitations and Caveats

No clinical testing, such as blood biomarkers, to correlate physiological data with observed outcomes, limiting conclusions about ashwagandha's biochemical effects on muscle strength and recovery. Sleep quality was self-reported - future studies should use objective methods. The convenience sample limits generalisability, and larger samples are needed. Lack of a crossover design also restricts control over confounders, and future research could benefit from this approach to reduce variability.

Results Point of Contact

Title
Olivia Coope
Organization
Blanquerna Institute - Universitat Ramon Llull

Study Officials

  • Blanca Roman Viñas

    Blanquerna, Ramon Llull University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Double-blind, placebo-controlled, randomised trial
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 31, 2024

First Posted

February 20, 2024

Study Start

January 13, 2024

Primary Completion

February 21, 2024

Study Completion

April 27, 2024

Last Updated

January 9, 2025

Results First Posted

January 9, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations